Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER3 | P43115 | 15/20 | 0.49 |
| ▸ | CACNA1H | O95180 | 3/20 | 0.38 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.37 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.37 |
| ▸ | CHKA | P35790 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1926719 | 0.82 | PTGER3 (0.56) | PTGER3 | |
| SCHEMBL1924422 | 0.81 | PTGER3 (0.52) | PTGER3 | |
| SCHEMBL1926683 | 0.79 | PTGER3 (0.49) | PTGER3 | |
| SCHEMBL1926685 | 0.79 | PTGER3 (0.49) | PTGER3 | |
| SCHEMBL1926098 | 0.77 | PTGER3 (0.56) | PTGER3 | |
| SCHEMBL1925005 | 0.75 | PTGER3 (0.52) | PTGER3 | |
| SCHEMBL5514366 | 0.74 | PTGER3 (0.44) | PTGER3CACNA1HCACNA1GCACNA1I | |
| SCHEMBL1925289 | 0.74 | PTGER3 (0.53) | PTGER3 | |
| SCHEMBL1924074 | 0.70 | PTGER3 (0.58) | PTGER3 | |
| SCHEMBL4317788 | 0.69 | PTGER3 (0.66) | PTGER3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1812426-B1 | ARYL SULFONAMIDE PERI-SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE | DECODE GENETICS EHF (IS) | 2011-06-08 | — | — | EP | disclosed |
| US-20090075985-A1 | ARYL SULFONAMIDE PERI-SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE | DECODE GENETICS INC. (US) | 2009-03-19 | — | — | US | disclosed |
| EP-1812426-A1 | ARYL SULFONAMIDE PERI-SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE | Decode Genetics, Inc. (US) | 2007-08-01 | — | — | EP | disclosed |
| US-20060142348-A1 | Aryl sulfonamide peri-substituted bicyclics for occlusive artery disease | DECODE CHEMISTRY, INC. (US) | 2006-06-29 | — | — | US | disclosed |
| WO-2006044405-A1 | ARYL SULFONAMIDE PERI-SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE | DECODE GENETICS, INC. (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142348-A1 | Aryl sulfonamide peri-substituted bicyclics for occlusive artery disease | PTGIS, PTGIR, TBXA2R | PTGER3 19/4885CACNA1H 2846/4885CACNA1G 2764/4885 |
| US-20090075985-A1 | ARYL SULFONAMIDE PERI-SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE | PTGIS, PTGIR, TBXA2R | PTGER3 19/4885CACNA1H 2846/4885CACNA1G 2764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.